Latest news
GOOD NEWS FROM EPO
The European Patent Organization, EPO, has announced its intention to approve (Intention to Grant) a patent for Iconovo's inhaler platform, ICOres.
Iconovo…
Iconovo mentioned in Biostock (only in Swedish)
Iconovos inhalatorer vinner mark när konkurrerande produktpatent löper ut
Med sina inhalationsprodukter adresserar Lundabolaget Iconovo ett marknadsvärde…
Press releases
Apr 24, 2025, 08:55
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 24, 2025, 08:37
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
Apr 24, 2025, 08:37
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
Apr 24, 2025, 08:35
News
IR
English
Regulatory
MAR
Corporate Action
Other
Apr 24, 2025, 08:35
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Mar 31, 2025, 08:30
News
IR
English
Corporate Action
Other
Mar 31, 2025, 08:30
News
IR
Swedish
Corporate Action
Other
Mar 03, 2025, 13:42
News
IR
English
Corporate Action
Other
Mar 03, 2025, 13:42
News
IR
Swedish
Corporate Action
Other
Feb 27, 2025, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 27, 2025, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Jan 13, 2025, 08:30
News
IR
English
Corporate Action
Other
Jan 13, 2025, 08:30
News
IR
Swedish
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
